NICE rejects Eisai’s Halaven in earlier setting for metastatic breast cancer
February 22, 2018Sales and Marketing Brest cancer, Cancer, Eisai, Halaven, NICE, pharma
NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast …
CDC U-turns previous decision on AZ’s flu vaccine
February 22, 2018Sales and Marketing AstraZeneca, Vaccine, biotech, drugs, flu, influenza, pharma, pharmaceutical
The US Centers for Disease Control and Prevention (CDC) has now recommended AstraZeneca’s FluMist as an option for doctors for …
Reports increasing of worrying side-effects with Regeneron’s Eylea
February 22, 2018Medical Communications, Research and Development, Sales and Marketing Eylea, FDA, Regeneron, pharma
Reports are emerging which detail some pretty alarming side-effects in patients receiving Regeneron’s blockbuster eye drug Eylea: once injected into …
Greek parliament moves to investigate 10 politicians
February 22, 2018Medical Communications, Sales and Marketing Greece, Greek Parliament, Novartis, biotech, drugs, pharma, pharmaceutical
After a 20-hour debate, Greek parliament has voted in favour of investigating 10 politicians named as part of an investigation …
MSD poised to acquire viral immuno-oncology firm Viralytics for $394m
February 21, 2018Research and Development, Sales and Marketing Cancer, MSD, Merck, Viralytics, acquisition, keytruda, oncology, pharma
MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …
AZ licenses kidney drug from Ionis for $330m
February 21, 2018Research and Development, Sales and Marketing AstraZeneca, Ionis, Isis, biotech, drugs, kidney, pharma, pharmaceutical
AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …
Aimmune’s peanut allergy candidate hits main endpoint at Phase 3
February 21, 2018Research and Development Aimmune, peanut, peanut allergy, pharma
US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial …
AbbVie turns to tau for Alzheimer’s in $1.1bn deal
February 21, 2018Research and Development, Sales and Marketing AbbVie, Alzheimer's, Voyager, biotech, drugs, pharma, pharmaceutical
Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …
Google develops AI to predict cardiovascular risk
February 21, 2018Research and Development AI, Verily Life Sciences, biotech, cardiovascular, drugs, google, pharma, pharmaceutical
Google and Verily Life Sciences, a subsidiary within Alphabet, focused on developing health-tech, have revealed the fruits of a combined …
NICE recommends thyroid cancer drug trio for NHS use
February 20, 2018Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer
NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …
Shire, Microsoft and EURORDIS form rare disease alliance
February 20, 2018Manufacturing and Production, Research and Development Microsoft, Shire, eurordis, pharma, rare disease
Rare disease specialist pharma firm Shire, rare disease patient alliance EURORDIS and tech giant Microsoft have announced they have formed …
Low flu vaccine efficacy may be due to previous immune history, study finds
February 20, 2018Manufacturing and Production, Research and Development H3N2, Vaccine, flu, flue vaccine, influenza, pharma
The sometimes poor efficacy of influenza vaccines may be due to poor immune response and a patient’s wider immune history, …
Japan’s Oncolys invests £3m in adenovirus firm Unleash Immuno Oncolytics
February 20, 2018Manufacturing and Production, Research and Development, Sales and Marketing Oncolys, Unleash Immuno Oncolytics, pharma
Unleash Immuno Oncolytics, a US firm focusing on the development of viral biologics in the treatment of cancer, has attracted …
Lilly dumps Hanmi’s rheumatoid arthritis med
February 20, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, arthritis, hanmi, pharma
Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, …
Patient experience: Living with multiple myeloma
February 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, feature, mutiple myeloma, patient experience, pharma
Pharmafocus talks to John Ellwood about the challenges of being diagnosed with multiple myeloma and how having a strong support …
Apricus shares sink after failed erectile dysfunction application
February 19, 2018Sales and Marketing Apricus, biotech, drugs, pharma, pharmaceutical
Apricus Biosciences had a lot riding on its application to the FDA for its erectile dysfunction cream, Vitaros, with the …
Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis
February 19, 2018Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis
Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …
Celgene reveals strong P3 Otezla data in rare inflammatory condition
February 19, 2018Research and Development, Sales and Marketing Behçet's disease, Celgene, apremilast, otezla, pharma
Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …
Long-running, $2.5bn lawsuit swings in Gilead’s favour
February 19, 2018Sales and Marketing Gilead, MSD, biotech, drugs, harvoni, pharma, pharmaceutical, sovaldi
The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …
AZ’s Imfinzi seals blockbuster lung cancer market with FDA nod
February 19, 2018Sales and Marketing AstraZeneca, Imfinzi, biotech, drugs, pharma, pharmaceutical
AstraZeneca’s immunotherapy, Imfinzi, arrived to the industry as a failure – there were big hopes resting on the company’s Mystic …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
